Every Form 4 that Tenet Healthcare Corporation New (THC) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow THC and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full THC filings page.
TENET HEALTHCARE CORP executive Paola M. Arbour, EVP and Chief Information Officer, reported acquiring 18,894 shares of common stock through a grant or award on February 13, 2026. The shares were issued at a stated price of $0.0000 per share, bringing her directly held total to 39,004 shares.
According to the disclosure, this grant represents performance-based restricted stock that was earned when the company’s Human Resources Committee certified that applicable performance targets were achieved for the performance period from January 1, 2023 to December 31, 2025.
Tenet Healthcare CEO Saumya Sutaria reported an equity award under the company’s incentive plan. He acquired 245,592 shares of common stock at no cost through a grant of performance-based restricted stock that was earned when the Human Resources Committee certified achievement of performance goals for the period from January 1, 2023 to December 31, 2025. Following this award, his directly held common stock position increased to 620,681 shares.
Tenet Healthcare’s principal accounting officer, Ramsey R. Scott, received an equity award. On the reported date, he acquired 9,448 shares of Tenet Healthcare common stock as a grant of performance-based restricted stock at a price of $0 per share.
Following this grant, his directly held common stock totaled 9,448 shares. The award was earned when the company’s Human Resources Committee certified that performance targets were achieved for the performance period from January 1, 2023 to December 31, 2025, based on the extent to which the applicable performance goals were attained.
Tenet Healthcare Corp executive Thomas W. Arnst reported an equity award of 37,785 shares of common stock. The Form 4 shows these shares were acquired at a price of $0.00 per share as a grant or award, bringing his directly held common stock to 37,785 shares.
According to the footnote, this represents performance-based restricted stock that was earned when the Human Resources Committee certified achievement of performance targets tied to goals measured over the period from January 1, 2023 to December 31, 2025.
Tenet Healthcare Corp reported an insider equity transaction by CEO and director Saumya Sutaria. On December 31, 2025, 13,016 restricted stock units converted into common stock on a one-for-one basis, increasing his directly held stake.
On the same date, 6,610 shares of common stock were withheld to cover taxes at a price of $198.72 per share. After these transactions, Sutaria directly owned 375,089 shares of Tenet common stock and held 39,049 time-based restricted stock units that continue to vest annually through 2028 under a January 23, 2025 grant.
Tenet Healthcare Corp director Nadja West reported selling 2,178 shares of the company’s common stock on 12/15/2025. The shares were sold at a weighted average price of $197.47 per share in multiple transactions, with prices ranging from $197.47 to $197.57. Following this sale, West beneficially owned 28,480 shares of Tenet Healthcare common stock directly.
Tenet Healthcare (THC): Insider stock sale disclosed. Principal Accounting Officer R. Scott Ramsey reported open-market sales of common stock on 11/06/2025. Transactions included 8,056 shares at a weighted average price of $204.75 (sold across $204.21–$205.13) and 5,066 shares at a weighted average price of $205.62 (sold across $205.21–$206.14), plus 200 shares at $206.51. After these sales, the table shows beneficial ownership of common stock at 0 shares. The filing lists transaction code “S” for sales and notes weighted-average pricing with details available upon request.
Tenet Healthcare (THC) director Tammy Romo reported an open market sale of company stock. On 11/05/2025, she sold 645 shares of common stock at $205.20 per share, according to a Form 4 insider filing. After this transaction, she directly owns 34,866 shares of Tenet Healthcare common stock.
Tenet Healthcare (THC) director Tammy Romo reported open‑market sales of 26,855 shares on November 3–4, 2025. Trades occurred in multiple transactions within a per‑share range of $200.00 to $204.93, with weighted‑average prices disclosed for each tranche.
Following these transactions, Romo beneficially owns 35,511 shares, held directly. The filing lists tranches of 8,654, 5,945, 500, 11,410 and 346 shares at weighted‑average prices of $200.43, $201.23, $202.27, $204.04 and $204.93, respectively.
Tenet Healthcare (THC) reported an insider transaction by a director. On 10/29/2025, the director sold 2,500 shares of common stock at $208.43 per share. After this sale, the director beneficially owns 8,792 shares, held directly.
The filing lists the reporting person as Richard W. Fisher, with the form signed by attorney-in-fact Chad J. Wiener on 10/31/2025.
Tenet Healthcare (THC) director J. Robert Kerrey reported a charitable transfer of company stock. On 10/29/2025, he disposed of 971 shares of common stock under transaction code G at $0. Following the transaction, he beneficially owns 21,406 shares, held directly. The filing notes the shares were contributed to the Fidelity Charitable Gift Fund.